MicroRNAs and target genes modulation in subjects with atrial fibrillation treated with apixaban or warfarin - AMO-M

FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE0 个研究点目标入组 50 人开始时间: 2021年2月5日最近更新: 2021年7月5日

适应症

试验速览

暂无简介。

•Men and post-menopause women of age 45 to 80 years with AF who need anticoagulation treatment.No contraindications to Apixaban and Warfarin as per registration. Presence of ischemic heart disease or diabetes (type II). Ability to understand and sign the informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 35

•Any acute or chronic condition (infections, cancer, chronic inflammatory diseases) that may interfere with microRNA assessment. Because of the policy of our Ethic Committee on Women of childbearing potential,no women of child bearing potential will be enrolled. •Malignant hypertension - •Patients without supervision and/or at high risk of low compliance to treatment.

发起方

FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE